[Suprapubic Nicolau syndrome following subcutaneous injection of glatiramer acetate]. / Dermite livédoïde de Nicolau sus-pubienne après injections sous-cutanées d'acétate de glatiramère.
Ann Dermatol Venereol
; 145(11): 671-675, 2018 Nov.
Article
de Fr
| MEDLINE
| ID: mdl-30217685
ABSTRACT
BACKGROUND:
Subcutaneous glatiramer acetate, commercialized under the name of Copaxone®, is licensed for the treatment of relapsing multiple sclerosis. Its major adverse effects are skin reactions at the injection site. Nicolau syndrome is a rare but serious iatrogenic accident. Herein we report a case seen in a setting of change of dosage and administration rate of Copaxone®. PATIENTS ANDMETHODS:
A 64-year-old woman, treated since 2010 with daily sub-cutaneous injections of Copaxone® 20mg/L, reported the appearance of a painful, indurated and erythematous plaque in the suprapubic area following changeover to 40mg/mL injections three times weekly. The suprapubic injections were continued and ugly greyish spots with stellate purpuric borders appeared. Fournier gangrene was ruled out by means of a soft tissue scan.DISCUSSION:
We report this latest case of Nicolau syndrome to alert readers to the non-exceptional nature of this complication associated with use of glatiramer acetate, particularly at a dosage of 40mg/L injections three times weekly. In our case, onset of Nicolau syndrome appears to have been favored by continued injection in areas already showing inflammation. Re-injection of the drug in these areas should thus be proscribed.Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Syndrome de Nicolau
/
Acétate de glatiramère
/
Immunosuppresseurs
Limites:
Female
/
Humans
/
Middle aged
Langue:
Fr
Journal:
Ann Dermatol Venereol
Année:
2018
Type de document:
Article